… RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced the … the Company’s Axiomer platform technology and pipeline of RNA editing programs as it enters the clinical stage. “We are …
… RNA therapies based on its proprietary Axiomer ™ RNA editing technology platform today announced that Company … Axiomer platform, the therapeutic potential of our Axiomer RNA editing oligonucleotides, and the potential of our …
… Operating and Financial Results Axiomer™ ADAR-mediated RNA editing pipeline advancing across liver and CNS programs, … poised to demonstrate the broad therapeutic potential of RNA editing. Our growing discovery pipeline, now including …
Initial AX-0810 data show no safety signals after 4 weeks of dosing and pharmacokinetics consistent with non-clinical data; Phase 1 enrollment and dosing in healthy volunteers ongoing with target engagement data expected in H1 2026, followed by inclusion of a patient cohort
Advancing AX-0810 through ongoing Phase 1 dosing, with target engagement data expected 1H 2026Selected Development Candidates AX-2402 for Rett syndrome (MECP2, R270X) and AX-2911 for MASH (PNPLA3)Ended 2025 with € 92.4 million cash and cash equivalents and achie
… NTCP for cholestatic diseases to be first ProQR Axiomer™ RNA editing program to enter the clinic Company to host … RNA therapies based on its proprietary Axiomer ™ RNA editing technology platform, today reported its financial …